Mauricio P Pinto
Overview
Explore the profile of Mauricio P Pinto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
540
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramirez-Parada K, Sanchez C, Cantarero-Villanueva I, Reyes A, Pinto M, Loreto Bravo M, et al.
Arch Phys Med Rehabil
. 2025 Mar;
PMID: 40081785
Objective: to evaluate if combining prospective surveillance model (PSM) with a supervised multimodal exercise program prevents breast cancer-related lymphedema (BCRL) and its impact on the functional capacity and quality of...
2.
Munoz-Medel M, Pinto M, Goralsky L, Caceres M, Villarroel-Espindola F, Manque P, et al.
Front Oncol
. 2024 May;
14:1403089.
PMID: 38807771
() is a gram-negative oral pathogen associated with chronic periodontitis. Previous studies have linked poor oral health and periodontitis with oral cancer. Severe cases of periodontal disease can result in...
3.
Valenzuela R, Walbaum B, Farias C, Acevedo F, Vargas C, Bennett J, et al.
Nutrition
. 2024 Mar;
121:112357.
PMID: 38430738
Objective: Polyunsaturated fatty acids are categorized as ω-3 or ⍵-6. Previous studies demonstrate that breast cancers display a high expression of fatty acid synthase and high fatty acid levels. Our...
4.
Walbaum B, Reyes J, Rodriguez P, Muniz S, Medina L, Ibanez C, et al.
Ecancermedicalscience
. 2024 Feb;
17:1636.
PMID: 38414945
Background: The addition of cyclin-dependent kinases inhibitors (CDKi) to endocrine therapy (ET) as the first- or second line treatment improves progression-free and overall survival (OS) in hormone receptor-positive, HER2 negative...
5.
Ramirez-Parada K, Gonzalez-Santos A, Riady-Aleuy L, Pinto M, Ibanez C, Merino T, et al.
Curr Oncol
. 2023 Sep;
30(9):8068-8077.
PMID: 37754500
Breast cancer-related lymphedema (BCRL) is characterized by arm swelling, pain, and discomfort, reducing the quality of life (QoL) of affected individuals. BRCL is caused via the blockage or disruption of...
6.
Acevedo F, Walbaum B, Camus M, Manzor M, Muniz S, Medina L, et al.
Breast Cancer Res Treat
. 2023 Mar;
199(2):363-370.
PMID: 36988750
Purpose: Latin American reports on genetic cancer risk assessments are scarce. In Chile, current breast cancer (BC) guidelines do not define strategies for germline genetic testing. Our study sought to...
7.
Mondaca S, Pinto M, Briones J, Caire N, Pena J, Koch E, et al.
Value Health Reg Issues
. 2023 Feb;
35:13-18.
PMID: 36805388
Objectives: Perioperative and adjuvant chemotherapy have demonstrated clinical benefits in localized gastric cancer. Nevertheless, the reports on their effects on patient's health-related quality of life (HRQoL) are scarce. Here, we...
8.
Pinto M, Munoz-Medel M, Retamal I, Bravo M, Latapiat V, Cordova-Delgado M, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613445
Recently, the combination of chemotherapy plus nivolumab (chemo-immunotherapy) has become the standard of care for advanced-stage gastric cancer (GC) patients. However, despite its efficacy, up to 40% of patients do...
9.
Acevedo F, Walbaum B, Muniz S, Petric M, Martinez R, Guerra C, et al.
Sci Rep
. 2022 Dec;
12(1):21145.
PMID: 36477462
Pathological complete response (pCR) after neoadjuvant chemotherapy (NCT) is associated with good long-term prognosis in breast cancer (BC) patients. However, some patients still recur and eventually die from this disease....
10.
Cordova-Delgado M, Pinto M, Pizarro G, Koch E, Vargas C, Hernandez M, et al.
J Gastrointest Oncol
. 2022 Sep;
13(4):2057-2064.
PMID: 36092312
Background: Early-onset gastric cancers (EOGC) are poor prognosis hard-to treat malignancies that affect young individuals (<45 years old). Case Description: Herein we describe the case of a 26-year-old female EOGC...